Timo Reisländer

708 total citations
10 papers, 494 citations indexed

About

Timo Reisländer is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Timo Reisländer has authored 10 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 2 papers in Surgery and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Timo Reisländer's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). Timo Reisländer is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers). Timo Reisländer collaborates with scholars based in Germany, France and Australia. Timo Reisländer's co-authors include Madalena Tarsounas, Florian J. Groelly, Adrian L. Harris, Emilia Puig Lombardi, Arturo Londoño‐Vallejo, Annamaria Biroccio, Manuela Porru, Benjamin Wright, Helen Lockstone and Ana Miar and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Molecular Cell.

In The Last Decade

Timo Reisländer

7 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Timo Reisländer Germany 5 282 224 223 83 67 10 494
Aitian Li China 7 328 1.2× 259 1.2× 265 1.2× 78 0.9× 98 1.5× 11 665
William R. Gwin United States 13 426 1.5× 295 1.3× 272 1.2× 58 0.7× 52 0.8× 34 669
Katie Palen United States 9 456 1.6× 245 1.1× 185 0.8× 175 2.1× 131 2.0× 20 665
Loryn Holokai United States 7 333 1.2× 128 0.6× 142 0.6× 133 1.6× 91 1.4× 12 528
Jenny Sprooten Belgium 10 317 1.1× 381 1.7× 248 1.1× 66 0.8× 88 1.3× 12 649
Emily Cheney United States 4 385 1.4× 275 1.2× 252 1.1× 24 0.3× 69 1.0× 5 573
Jessica Michie Australia 8 330 1.2× 329 1.5× 225 1.0× 51 0.6× 47 0.7× 10 545
Ronan Thibaut France 6 237 0.8× 195 0.9× 137 0.6× 68 0.8× 44 0.7× 7 428
Yongxiang Yan China 8 356 1.3× 332 1.5× 203 0.9× 46 0.6× 59 0.9× 12 619
Amirhossein Mardi Iran 11 190 0.7× 129 0.6× 164 0.7× 51 0.6× 96 1.4× 30 411

Countries citing papers authored by Timo Reisländer

Since Specialization
Citations

This map shows the geographic impact of Timo Reisländer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timo Reisländer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timo Reisländer more than expected).

Fields of papers citing papers by Timo Reisländer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timo Reisländer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timo Reisländer. The network helps show where Timo Reisländer may publish in the future.

Co-authorship network of co-authors of Timo Reisländer

This figure shows the co-authorship network connecting the top 25 collaborators of Timo Reisländer. A scholar is included among the top collaborators of Timo Reisländer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timo Reisländer. Timo Reisländer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Karthaus, Meinolf, Volker Heinemann, Jorge Riera‐Knorrenschild, et al.. (2024). Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. BMC Cancer. 24(1). 887–887.
2.
Zhang, Danmei, Klara Dorman, C. Benedikt Westphalen, et al.. (2024). Unresectable biliary tract cancer: Current and future systemic therapy. European Journal of Cancer. 203. 114046–114046. 8 indexed citations
3.
Muller, Christian D., Sabine Franke, Timo Reisländer, Verena Keitel, & Marino Venerito. (2024). Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports. SHILAP Revista de lepidopterología. 17(1). 753–762.
4.
Wyrwicz, Lucjan, Julien Taı̈eb, Timothy Price, et al.. (2023). Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies. 12(3). 1 indexed citations
5.
6.
Karthaus, Meinolf, Jorge Riera‐Knorrenschild, A. Kretzschmar, et al.. (2022). Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial. ESMO Open. 7(1). 100391–100391. 9 indexed citations
7.
Wyrwicz, Lucjan, Jean‐Baptiste Bachet, Meinolf Karthaus, et al.. (2022). SO-18 Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies. Annals of Oncology. 33. S364–S364. 2 indexed citations
8.
Reisländer, Timo, Florian J. Groelly, & Madalena Tarsounas. (2020). DNA Damage and Cancer Immunotherapy: A STING in the Tale. Molecular Cell. 80(1). 21–28. 229 indexed citations
9.
Reisländer, Timo, Emilia Puig Lombardi, Florian J. Groelly, et al.. (2019). BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nature Communications. 10(1). 3143–3143. 137 indexed citations
10.
Herter, Sylvia, Laura Morra, Ramona Schlenker, et al.. (2016). A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunology Immunotherapy. 66(1). 129–140. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aitian Li Breakdown of academic impact, for papers by William R. Gwin Breakdown of academic impact, for papers by Katie Palen Breakdown of academic impact, for papers by Loryn Holokai Breakdown of academic impact, for papers by Jenny Sprooten Breakdown of academic impact, for papers by Emily Cheney Breakdown of academic impact, for papers by Jessica Michie Breakdown of academic impact, for papers by Ronan Thibaut Breakdown of academic impact, for papers by Yongxiang Yan Breakdown of academic impact, for papers by Amirhossein Mardi
Rankless by CCL
2026